Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
Executive Summary
US FDA sees role for postmarketing data to help address residual uncertainties and determine additional data needs, but not as basis for securing an interchangeability designation absent a clinical, multi-switching study, draft guidance states.
You may also be interested in...
New Supplement Timelines, Categories Proposed For BsUFA III
The ideas could potentially address sponsor concerns about the effects of slow reviews.
New Supplement Timelines, Categories Proposed For BsUFA III
The ideas could potentially address sponsor concerns about the effects of slow reviews.
Best Pathway To Interchangeable Insulins Is In The Eye Of The Beholder
Approaches suggested at a US FDA public hearing include allowing follow-on insulins to take a direct route to interchangeability without first having to be approved as biosimilars, and automatically declaring biosimilar insulins interchangeable with one or more reference products.